Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15514844 | 0.90 | PDE4B (0.47) | ALDH1A1PDE4BEGFRERBB2PDE4A | |
| SCHEMBL4224358 | 0.86 | PDE4B (0.48) | ALDH1A1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2581353 | 0.83 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4213774 | 0.82 | RBP4 (0.41) | — | |
| SCHEMBL31378914 | 0.81 | MAPT (0.50) | ALDH1A1PDE4BKDM4EGAAMAPT | |
| SCHEMBL4519218 | 0.78 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4202107 | 0.77 | PDE4B (0.59) | ALDH1A1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4202110 | 0.77 | PDE4B (0.59) | ALDH1A1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15509004 | 0.77 | PDE4B (0.59) | ALDH1A1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15321287 | 0.74 | PDE4D (0.42) | PDE4BGAAPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
| EP-2029609-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146758-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | ALDH1A1 1267/4885PDE4B 1851/4885KDM4E 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.